Can you get rid of gynaecomastia without surgery? For many men and boys, this is a pressing concern — and the good news is that non-surgical options do exist. Gynaecomastia, the benign enlargement of glandular breast tissue in males, can sometimes resolve on its own or respond to medical treatment, particularly when caught early. The right approach depends on the underlying cause, how long the condition has been present, and the type of tissue involved. This article outlines the causes, non-surgical treatments, lifestyle changes, and when surgery may still be the most appropriate path forward.

What Causes Gynaecomastia and Who Is Affected

Gynaecomastia is caused by an imbalance between oestrogen and androgen activity in breast tissue and can be triggered by medications, hormonal conditions, recreational substances, or idiopathic factors across all age groups.

Have any more questions about this? Message our pharmaceutical team to get more info →

Gynaecomastia is the benign enlargement of glandular breast tissue in males, resulting from an imbalance between oestrogen and androgen activity in breast tissue. It may be unilateral or bilateral, and the early phase is often tender. It is distinct from pseudogynecomastia, which refers to fat accumulation in the chest area without true glandular growth. Understanding the underlying cause is essential before considering any treatment pathway.

The condition is common across all age groups:

• Neonates may experience transient gynaecomastia due to maternal oestrogens

• Adolescents are frequently affected during puberty; studies suggest a substantial proportion of teenage boys develop some degree of breast tissue enlargement, though estimates vary widely by age group and diagnostic criteria (NICE CKS: Gynaecomastia)

• Older men may develop it due to declining testosterone levels and relative oestrogen excess

A wide range of factors can contribute to gynaecomastia, including:

• Medications such as spironolactone, cimetidine, anti-androgens (e.g., bicalutamide), 5-alpha-reductase inhibitors (e.g., finasteride, dutasteride), antiretrovirals, digoxin, verapamil, anabolic steroids, antipsychotics, and some antihypertensives

• Medical conditions including hypogonadism, hyperthyroidism, liver cirrhosis, and chronic kidney disease

• Recreational substances such as cannabis, alcohol, and anabolic steroids

• Idiopathic causes, where no clear trigger is identified

In many adolescent cases, gynaecomastia resolves spontaneously within one to two years without any intervention. However, persistent or symptomatic cases — particularly those causing pain, tenderness, or significant psychological distress — warrant clinical evaluation. A GP assessment is the appropriate first step to rule out secondary causes and guide management.

Further information: NICE CKS: Gynaecomastia; NHS: Enlarged male breasts (gynaecomastia)

Non-Surgical Treatment Options Available in the UK

Non-surgical options — including addressing the underlying cause, watchful waiting, off-label medications, and compression garments — are most effective when gynaecomastia is recent in onset and glandular fibrosis has not yet occurred.

For many men and boys, the question of whether gynaecomastia can be resolved without surgery is a reasonable and important one. The answer depends largely on the underlying cause, the duration of the condition, and the degree of glandular versus fatty tissue involved. Non-surgical approaches are most effective when gynaecomastia is recent in onset, mild to moderate in severity, or linked to an identifiable and reversible cause.

Addressing the underlying cause is often the most effective non-surgical strategy. If a medication is identified as the trigger, a GP may consider switching to a clinically appropriate alternative where possible — for example, replacing spironolactone with eplerenone in suitable patients. Similarly, treating an underlying hormonal disorder — such as hypogonadism or hyperthyroidism — can lead to regression of breast tissue over time.

For adolescents with pubertal gynaecomastia, a period of watchful waiting is typically recommended, as the majority of cases resolve naturally within 12 to 24 months. During this time, reassurance and monitoring are the primary interventions.

Non-surgical options available in the UK include:

• Pharmacological treatment with anti-oestrogens or aromatase inhibitors, used off-label in specialist care (discussed in the next section)

• Compression garments, which do not treat the condition but can reduce visible appearance and improve confidence

• Psychological support, particularly for adolescents experiencing distress related to body image

Non-surgical treatments are generally most effective during the active or proliferative phase of gynaecomastia — typically within the first 12 months of onset — before fibrous stromal tissue replaces the glandular component. Once fibrosis has occurred, the tissue is considerably less likely to respond to medical therapy. A defined review period of three to six months is reasonable to assess whether non-surgical strategies are producing benefit.

Further information: NICE CKS: Gynaecomastia; NHS: Enlarged male breasts (gynaecomastia)

Medications Used to Treat Gynaecomastia

Tamoxifen is the most widely used off-label pharmacological treatment for gynaecomastia in the UK, initiated by specialists; no medication is currently licensed for this indication, and self-medicating carries significant safety risks.

Although no medication is currently licensed specifically for gynaecomastia in the UK, several drugs are used off-label in clinical practice, typically initiated by specialists in endocrinology or breast surgery. Their use should always be guided by a qualified clinician following a thorough assessment, and availability may vary according to local integrated care board (ICB) policies.

Tamoxifen, a selective oestrogen receptor modulator (SERM), is the most widely studied pharmacological option. It works by competitively blocking oestrogen receptors in breast tissue, thereby reducing the oestrogenic stimulus for glandular proliferation. Clinical evidence suggests tamoxifen can reduce breast volume and tenderness in a significant proportion of patients, particularly when used early in the course of the condition. A typical regimen used in specialist practice is 10–20 mg once daily for three to six months, with periodic review. It is generally well tolerated; however, important cautions include an increased risk of thromboembolic events (particularly in patients with additional VTE risk factors or during periods of immobility), hot flushes, nausea, and interactions with anticoagulants such as warfarin. Patients taking tamoxifen alongside warfarin require close INR monitoring (BNF; MHRA/EMC SmPC: Tamoxifen).

Raloxifene, another SERM, has shown some efficacy in small, largely uncontrolled studies and may be considered as an off-label alternative in selected cases. The evidence base is limited and should be interpreted with caution (MHRA/EMC SmPC: Raloxifene).

Aromatase inhibitors such as anastrozole or letrozole reduce the peripheral conversion of androgens to oestrogens. Clinical trial evidence for their use in gynaecomastia is generally weak, and they are not recommended for pubertal gynaecomastia. Their use outside specialist care is not routinely advised (MHRA/EMC SmPC: Anastrozole/Letrozole; BNF).

Key points regarding medication use:

• These drugs are unlicensed for this indication and are typically initiated by a specialist; local prescribing policies vary

• Treatment is most effective during the early, active phase of the condition (within the first 12 months)

• Self-medicating with these agents — including sourcing them online — carries significant safety risks and is strongly discouraged

• Any pharmacological treatment should be reviewed and monitored by a GP or specialist

• If you experience suspected side effects from any medicine, these can be reported via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk

There is no reliable evidence that over-the-counter supplements marketed for testosterone support produce clinically meaningful reduction of gynaecomastia.

Lifestyle Changes That May Help Reduce Breast Tissue

Weight management, regular exercise, reducing alcohol intake, and stopping anabolic steroid or cannabis use can support hormonal balance but are unlikely to eliminate established glandular gynaecomastia on their own.

Lifestyle modifications play a supportive role in managing gynaecomastia, particularly in cases where pseudogynecomastia (fatty tissue) contributes significantly to the chest appearance, or where modifiable risk factors are present.

Weight management is one of the most impactful lifestyle interventions. Adipose tissue contains aromatase enzymes that convert androgens into oestrogens, meaning that excess body fat can perpetuate hormonal imbalance. Achieving and maintaining a healthy body weight through a balanced diet and regular physical activity may help reduce this peripheral oestrogen production. However, it is important to set realistic expectations — weight loss alone will not eliminate true glandular gynaecomastia, though it may improve the overall chest contour.

Exercise, particularly resistance training targeting the pectoral muscles, can improve chest definition and reduce the visual prominence of breast tissue. Whilst it does not directly reduce glandular tissue, it can have a meaningful impact on appearance and self-confidence.

Several lifestyle factors are known to contribute to or worsen gynaecomastia and should be addressed:

• Alcohol consumption — excessive intake can impair hepatic oestrogen metabolism and lower testosterone levels. The UK Chief Medical Officers recommend keeping alcohol consumption to no more than 14 units per week, spread over three or more days, to keep health risks low. Support to reduce alcohol intake is available via your GP or the NHS

• Cannabis use — associated with gynaecomastia in some studies, though the evidence for a causal relationship remains limited and uncertain

• Anabolic steroid use — a well-established cause; cessation is strongly advised

• Dietary phytoestrogens — whilst some concern exists around phytoestrogens in foods such as soya, current evidence from the British Dietetic Association does not support a clinically significant effect at normal dietary intake levels

Adopting a healthy lifestyle supports overall hormonal health and may complement other treatment strategies, but it is unlikely to resolve established glandular gynaecomastia on its own.

When to See a GP and What to Expect on the NHS

See a GP if gynaecomastia persists beyond three to six months, causes pain, or involves a hard lump or nipple discharge; NHS management follows a stepwise approach from identifying reversible causes to specialist referral.

Seeking a GP assessment is an important step for anyone concerned about gynaecomastia, particularly if the condition is persistent, painful, or causing significant psychological distress. Whilst many cases are benign and self-limiting, a clinical evaluation is necessary to exclude underlying pathology.

You should contact your GP if you notice:

• Breast tissue enlargement that has persisted for more than three to six months

• Breast pain or tenderness

• A hard, irregular, or rapidly growing lump — which requires prompt assessment to exclude breast cancer (rare in males but possible)

• Nipple discharge, particularly if blood-stained

• Skin or nipple changes, or palpable axillary lymph nodes

• Associated symptoms such as fatigue, changes in libido, or testicular abnormalities

In line with NICE NG12 (Suspected cancer: recognition and referral), a two-week-wait urgent referral to a specialist breast service should be considered where there is a suspicious hard or irregular mass, blood-stained nipple discharge, skin or nipple changes, or palpable axillary nodes in a male patient.

During a GP consultation, you can expect a thorough history and physical examination. The GP may arrange blood tests to assess hormone levels — including early-morning (8–10 am) testosterone, LH, FSH, oestradiol, prolactin, and thyroid function — as well as liver and kidney function. Where a secondary cause such as a germ cell tumour is suspected, tumour markers including beta-hCG and AFP should also be measured. Breast ultrasound, with or without mammography according to age, clinical suspicion, and local protocol, may be requested if a secondary cause is suspected.

On the NHS, management will typically follow a stepwise approach:

1. Identification and treatment of reversible causes
2. Watchful waiting for adolescent or recent-onset cases
3. Referral to an endocrinologist or breast surgeon for persistent or severe cases

NICE does not currently have a dedicated guideline specifically for gynaecomastia, but management is guided by established clinical practice and relevant NICE guidance on related conditions, including NICE CKS: Gynaecomastia. NHS surgical treatment for gynaecomastia is available but subject to local integrated care board (ICB) funding policies and individual funding request (IFR) processes, and access may vary by region.

Further information: NICE NG12: Suspected cancer: recognition and referral; NICE CKS: Gynaecomastia; NHS: Enlarged male breasts (gynaecomastia)

When Surgery May Still Be the Recommended Option

Surgery is recommended when gynaecomastia is long-standing, severe, or unresponsive to medical treatment, with subcutaneous mastectomy and liposuction being the standard procedures depending on tissue composition.

Whilst non-surgical approaches are appropriate for many patients, there are circumstances in which surgery remains the most effective — and sometimes the only — realistic option for resolving gynaecomastia. Understanding when surgery is indicated helps set appropriate expectations and supports informed decision-making.

Surgery is most likely to be recommended in the following situations:

• Long-standing gynaecomastia (typically present for more than 12 months), where fibrous tissue has replaced the glandular component and is unlikely to respond to medical therapy

• Severe gynaecomastia, involving significant skin excess or marked breast ptosis that cannot be adequately addressed non-surgically

• Failure of medical treatment, where pharmacological or lifestyle interventions have not produced satisfactory results

• Significant psychological impact, including severe impairment of quality of life

• Underlying pathology such as a hormone-secreting tumour, where surgical management of the primary cause is required

The standard surgical procedures for gynaecomastia include subcutaneous mastectomy (surgical excision of glandular tissue) and liposuction (for fatty tissue), or a combination of both depending on tissue composition. It is important to note that liposuction alone may be insufficient where dense glandular tissue is present; excision is typically required in such cases. As with any surgical procedure, risks include haematoma, infection, contour irregularity, altered nipple–areola sensation, scarring, and the possibility of revision surgery. Patients should discuss these risks and have realistic expectations before proceeding.

On the NHS, surgical treatment is typically only funded where strict ICB criteria are met, and many patients opt for treatment in the private sector. If considering private surgery, it is advisable to consult a surgeon on the GMC Specialist Register with specific experience in gynaecomastia correction. Patient information from BAAPS (British Association of Aesthetic Plastic Surgeons) or BAPRAS (British Association of Plastic, Reconstructive and Aesthetic Surgeons) can help you understand what to expect and how to choose a qualified surgeon.

Ultimately, the decision between non-surgical and surgical management should be made collaboratively between the patient and their clinical team, taking into account the severity of the condition, the likely tissue composition, treatment history, and individual patient goals.

Further information: NHS: Breast reduction for men (gynaecomastia); BAAPS/BAPRAS patient information on gynaecomastia surgery; GMC Specialist Register

Frequently Asked Questions